Evidence map›Paper›PMID 32717613›Full record

ArticleBioorganic & medicinal chemistry letters2020

Development of chiral fluorinated alkyl derivatives of emixustat as drug candidates for the treatment of retinal degenerative diseases.

Eliav Blum, Jianye Zhang, Edward Korshin, Krzysztof Palczewski, Arie Gruzman

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioorganic & medicinal chemistry letters, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 90% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Advances and therapeutic opportunities in visual cycle modulation.Progress in retinal and eye research · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Eliav BlumDepartment of Chemistry, Faculty of Exact Sciences, Bar-Ilan University, Ramat-Gan 5290002, Israel.
Jianye ZhangGavin Herbert Eye Institute, Department of Ophthalmology, University of California, Irvine, CA 92697, USA.
Edward KorshinDepartment of Chemistry, Faculty of Exact Sciences, Bar-Ilan University, Ramat-Gan 5290002, Israel.
Krzysztof PalczewskiGavin Herbert Eye Institute, Department of Ophthalmology, University of California, Irvine, CA 92697, USA; Departments of Physiology and Biophysics, and Chemistry, University of California, Irvine, CA 92697, USA.
Arie GruzmanDepartment of Chemistry, Faculty of Exact Sciences, Bar-Ilan University, Ramat-Gan 5290002, Israel. Electronic address: gruzmaa@biu.ac.il.
Bar-Ilan University · ILUniversity of California, Irvine · US

Funding

STRUCTURAL STUDIES OF ARRESTINSR01EY009339 · NEI · UNIVERSITY OF WASHINGTON · PI KISER, PHILIP DAVID, PALCZEWSKI, KRZYSZTOF · 1992 to 2025
$16.0M
NEI NIH HHS R01 EY009339
6 · The paper itself

Abstract

The discovery of how a photon is converted into a chemical signal is one of the most important achievements in the field of vision. A key molecule in this process is the visual chromophore retinal. Several eye diseases are attributed to the abnormal metabolism of retinal in the retina and the retinal pigment epithelium. Also, the accumulation of two toxic retinal derivatives, N-retinylidene-N-retinylethanolamine and the retinal dimer, can damage the retina leading to blindness. RPE65 (Retinal pigment epithelium-specific 65 kDa protein) is one of the central enzymes that regulates the metabolism of retinal and the formation of its toxic metabolites. Its inhibition might decrease the rate of the retina's degeneration by limiting the amount of retinal and its toxic byproducts. Two RPE65 inhibitors, (R)-emixustat and (R)-MB001, were recently developed for this purpose.

Indexed as

Alkanescis-trans-IsomerasesEnzyme InhibitorsHalogenationHumansIsomerismModels, MolecularMolecular ConformationPharmaceutical PreparationsPhenyl EthersPropanolaminesRetinaRetinal DegenerationRetinaldehydeRetinoid IsomerohydrolaseStructure-Activity RelationshipAlkanescis-trans-IsomerasesemixustatEnzyme InhibitorsPharmaceutical PreparationsPhenyl EthersPropanolaminesRetinaldehyderetinal dimerRetinoid IsomerohydrolaseFluorinated alkyles(R)-emixustatRetinalRetinal degeneration(R)-MB001RPE65 (Retinal pigment epithelium-specific 65 kDa protein

Identifiers

PMID32717613
PMCPMC7494577
OpenAlexW3042550950

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.